BridgeMD
Compares treatment options for Multiple Sclerosis
Official title Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
ClinicalTrials.gov ID: NCT05754593
What this study is testing
What is Anti-Mullerian hormone (AMH) level?
Anti-Mullerian hormone (AMH) level is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for multiple sclerosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 35, women only. Healthy volunteers may be eligible.
You may be able to join if
- Reproductive women between 25 and 35 years old ;
- MS Patient : Diagnosis of multiple sclerosis based on McDonald Criteria 2017;
- French-speaking, without comprehension disorders ;
- being affiliated to health insurance ;
- Willing to participate and to sign informed consent.
You likely can't join if
- History of ovarian surgery (cystectomy, annexectomy) ;
- Turner Syndrome ;
- fragile X messenger ribonucleoprotein 1 (FMR1) premutation ;
- Endometriosis with a risk of ovarian reserve alteration ;
- History of chemotherapy or pelvic radiotherapy ;
- Pregnant or breastfeeding women ;
See the full eligibility criteria
- Reproductive women between 25 and 35 years old ;
- MS Patient : Diagnosis of multiple sclerosis based on McDonald Criteria 2017;
- French-speaking, without comprehension disorders ;
- being affiliated to health insurance ;
- Willing to participate and to sign informed consent.
- History of ovarian surgery (cystectomy, annexectomy) ;
- Turner Syndrome ;
- fragile X messenger ribonucleoprotein 1 (FMR1) premutation ;
- Endometriosis with a risk of ovarian reserve alteration ;
- History of chemotherapy or pelvic radiotherapy ;
- Pregnant or breastfeeding women ;
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to...
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 25 years to 35 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.